A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
Status:
Completed
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, and parallel study. The study is
comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about
14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase.
Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000
mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at
the end of the study.